Optomed - Terveysteknologiayhtiö

Paljon puhuttu että maailman mittakaavassa diabetes kasvaa väestössä, samaa tapahtuu myös meillä täällä kotimaassa.

4 tykkäystä

Pilotit ja testit tehty, jahka fda-lupa heltiää, todnäk UMASS:ilta pärähtää uutiset ensimmäisenä. Potentiaalia luulisin olevan satojen kameroiden tilaukselle pelkästään täältä.

Our research aims to implement a novel AI that overcomes these limitations and improve diabetic retinal screening. We have partnered with the digital health company AEYE Health to test the diagnostic accuracy of a hand-held AI-assisted non-mydriatic funduscopic camera to be used in the primary care setting to screen at-risk individuals for retinal changes indicative of diabetic retinopathy. AEYE AI algorithm just received FDA clearance and we are in the final stage of implementing this technology in the primary care setting.

Juan Ding, OD, PhD and James Ledwith, MD, FAAFP?

14 tykkäystä

Aeye Health on julkaissut uuden tutkimuksen DR:n ennustettavuudesta silmänpohjakuvan perusteella. Lupaavia tuloksia, ja voi tuoda tulevaisuudessa lisäarvoa Aeyen palvelulle.

Predicting the future development of diabetic retinopathy using a deep learning algorithm for the analysis of non-invasive retinal imaging
….
Conclusion Our results suggest that risk of DR may be predicted from fundus photography alone. Prediction of personalised risk of DR may become key in treatment and contribute to patient compliance across the board, particularly when supported by further prospective research.
….

Discussion

The aim of this research was to develop a method of predicting the chances of future development of DR, before detection methods can even be applied. Given the relatively high prevalence of DR,2 the difficulty in permanently reversing retinal damage,26and current patient non-compliance,8–11 prevention and not only treatment of DR is crucial to health outcomes. As such, prediction of individual DR risk may become a key element. Currently, to the best of our knowledge, there are two methods of doing this: risk factor based, which is of limited predictive clinical utility,19 20 and that developed by Bora et al, 21 which uses both deep learning and risk factors for optimal results.

13 tykkäystä

Omistajalistaa päivitetty. Useita sijoitusrahastoja sekä Kakkonen, Kaloniemi, Syrjälä lisänneet todella reippaalla otteella Optomedia salkkuihin suunnatusta annista. Kiinnostusta siis riittää!

20 tykkäystä

Ehkä parasta antia rahastot ja eläkevakuutusyhtiö elo…heille meni leijonan osa annista ja hyvä näin. Nämä ei ihan heti myy osakkeita tai laita treidaukseen…

2 tykkäystä

UMASS:in retinopatiaseulontaan on saatu lisärahoitusta.:

Herman G. Berkman Diabetes Clinical Innovation Fund Grant Awarded to Test Efficacy and Impact of a Diabetic Retinopathy Screening Program in Primary Care

Date Posted: Tuesday, January 03, 2023

The fourth annual Herman G. Berkman Diabetes Clinical Innovation Fund grant was awarded to optometrist Juan Ding, OD, PhD and co-investigator James Ledwith, MD, Department of Family Medicine and Community Health. Their project titled "Efficacy and Impact of Implementing an AI Diabetic Retinopathy Screening Program in Family Medicine Clinics" offers a path to identify eye disease and improve comprehensive care for people living with diabetes.

The Berkman Fund was established by UMass Memorial Health and the Diabetes Center of Excellence to support the development of diabetes care initiatives that would not normally get funded through traditional operational expenses or research grants. Herman Gerald Berkman, PhD, believed in the mission and care model of the UMass Diabetes Center of Excellence. His estate continues to provide support through this fund.

“Despite vast improvements in screening and treatment of diabetic retinopathy in previous years, it remains a leading cause of vision loss in the United States,” said Dr. Ding, Director of Optometry Service, UMass Eye Center. “Many people face barriers to accessing quality eye care, including income, transportation, and health insurance. It’s important to improve methods of screening for diabetic retinopathy and make it widely available.”

Recent studies have identified artificial intelligence (AI)-based algorithms as promising tools for the screening and early identification of diabetic retinopathy to help those at-risk. Various algorithms are being developed and must be evaluated before they can be used clinically.

UMass Memorial Health partnered with digital health company AEYE Health to test the diagnostic accuracy of a hand-held AI-assisted camera to be used by primary care physicians to screen at-risk individuals for retinal changes indicative of diabetic retinopathy.

The Berkman Fund will allow for efficient retinal imaging at primary care locations. It will also support analyzing the impact of offering primary care screening and its sustainability.

“This technology may also be offered to patients within the Diabetes Center of Excellence to screen for eye disease so we can address it immediately,” said Dr. Ding.

14 tykkäystä

@Juha_Kinnunen kirjoitti hyvän yhtiöraportin Optomedista. :slight_smile:

Optomedin osake on noussut edellisestä päivityksestämme yli 40 %, mitä kautta Optomedin aiemmin erittäin houkutteleva riski/tuotto-suhde on heikentynyt. Mielestämme näkymä on edelleen positiivinen odottaessamme Aurora AEYE:n FDA-lupaa Q1’23:n lopussa, minkä jälkeen oletettavasti alkaa ratkaisun monimutkaisempi kaupallistaminen Yhdysvalloissa. Kassaa yhtiö on paikannut osakeannilla, mikä pienentää aiemmin selkeää rahoitusriskiä. Riskiprofiili on silti edelleen erittäin korkea Aurora AEYE:n menestyksen ollessa kaukana varmasta.

image

https://www.inderes.fi/fi/odottavassa-tunnelmassa-vuoteen-2023

16 tykkäystä

Hyvä rapsa, kiitos!

Thirona eriyttää Thirona Retinan omaksi yhtiökseen. Tiedonhippunen samasta jutusta, ilmeisesti myös Thirona on Optomedin AI-kumppani, koska Optomed on mukana kumppanilistauksessa.

7 tykkäystä

Tässä on vielä aamarikommentti Juhalta. :slight_smile:

Laskemme Optomedin suosituksen lisää-tasolle (aik. osta), mutta nostamme tavoitehintamme 4,8 euroon (aik. 4,0 €). Osake on noussut edellisestä päivityksestämme yli 40 %, mitä kautta Optomedin aiemmin erittäin houkutteleva riski/tuotto-suhde on heikentynyt. Mielestämme näkymä on edelleen positiivinen odottaessamme Aurora AEYE:n FDA-lupaa Q1’23:n lopussa, minkä jälkeen oletettavasti alkaa ratkaisun monimutkaisempi kaupallistaminen Yhdysvalloissa. Kassaa yhtiö on paikannut osakeannilla, mikä pienentää aiemmin selkeää rahoitusriskiä. Riskiprofiili on silti edelleen erittäin korkea Aurora AEYE:n menestyksen ollessa kaukana varmasta.

11 tykkäystä

UCDavis Health alkaa jalkauttaa etäseulontoja perusterveydenhuoltoon. Tässä vaiheessa ilmeisesti hyödynnetään etälausuntoja, ja myöhemmin AI tulee mukaan kuvioon. Kyllähän tämä retinopatian seulonnan laajentaminen perusterveydenhuoltoon etenee ihan kuten Kopsala on haastatteluissa kertonutkin.

UC Davis Health leads $2M program to improve eye care for people with diabetes

By Lisa Howard

Program with other UC medical centers expands remote eye screenings to prevent blindness, particularly in underserved communiti

The goal is to expand eye care access for diabetics, particularly for underserved populations. The project will utilize digital medical equipment for teleophthalmology or “remote” ophthalmology.

How teleophthalmology can be used for screenings

A key feature of the CUTI program is integrating digital eye screenings into routine care at primary care facilities or clinics for patients with diabetes.

After the digital image is taken at the primary care office or clinic, the results are sent to an off-site eye care provider for evaluation and diagnosis.

“Teleophthalmology provides a convenient way to get your eyes screened for diabetic retinopathy and other ocular disorders during a routine visit to the primary care physician,” Yiu said. “It also enhances eye care access for those who do not live near an ophthalmologist.”

Since launching a separate pilot teleophthalmology program at UC Davis in 2018, Yiu has improved diabetic eye screening rates by more than 15%, helping to make UC Davis Health one of the top performers in the country.

The retinal images taken during the four-year study will be collected in a centralized repository for research using artificial intelligence. Artificial intelligence may be able to identify eye diseases and predict the risk of cardiovascular events and strokes — simply from images of the eye’s interior.

“The introduction of artificial intelligence is another exciting development in teleophthalmology,” Yiu said. “The incorporation of AI for automated image interpretation allows for faster and more sensitive diagnosis of early eye disease.”

Remote diabetic eye screening is already available at UC Davis primary clinics in Midtown, Folsom, Elk Grove, and the Lawrence E. Ellison Ambulatory Care Center. Yiu and his team believe that remote eye imaging may be used in the future to screen for other eye conditions such as glaucoma and age-related macular degeneration (AMD). Over the four-year program, they hope to spread the word to improve awareness about preventative eye care.

“We are excited to start this project and hope to find a way to scale it up for all of California. Our long-term goal is to make it easy for people with diabetes to get their annual eye screening, so we can help people avoid preventable blindness.”

18 tykkäystä

Modulight sai FDA-luvan silmälääkkeen silmässä aktivoivalle laserilleen. Tällä hetkellä markkina-arvo näyttäisi olevan reilut 100M€, liikevaihtoa firmalla oli 2021 9M€. Ei nyt ihan 1:1 verrokki Optomediin (markkina-arvo 69M€), mutta FDA-lupa nosti kurssia rivakat +40%. Odottelisin samansuuntaista reaktiota Optollekin, jos ja kun lupa tulee.

22 tykkäystä

Optomedin tärkein AI-kumppaninAeye Health tiedottaa (varsinainen artikkeli on jo ollut palstalla).

NEW YORK, Jan. 24, 2023 /PRNewswire/ – AEYE Health, a leading AI company for retinal-based diagnostics, is pleased to announce the recent publication of its paper describing the development of a deep learning algorithm which can accurately predict the future development of diabetic retinopathy in patients without any diagnosable retinopathy symptoms.

The paper was published in the British Medical Journal (BMJ), a peer-reviewed publication.

The research presents an artificial intelligence (AI) machine learning model which can predict the development of referable DR. The model does so using fundus imagery of otherwise healthy eyes, and boasts high efficacy, featuring an area-under-the-receiver-operating-curve (AUC) of above 0.81.

The significance of this study lies in the fact that not only can AI diagnose existing disease, it can also accurately predict the future development of a disease from subtle clues in the retinal image that human experts cannot discern. No additional input was given to the AI system aside from the retinal images.

Beyond the technical achievement for AI technology, disease prediction has significant clinical benefits. With an accurate indication for which patients are at high-risk for developing a disease, screening protocols can be adapted, allowing doctors to more closely monitor high-risk patients. Preventative treatment might also be considered in order to avoid the disease altogether, or mitigate effects. Similarly, very low-risk patients may be advised to undergo screening every 24 months, rather than current guidelines which advise annual screening.

This publication came two months following AEYE’s FDA clearance for diabetic retinopathy screening. AEYE’s best-in-class technology showed, for the first time, sensitivity and specificity above 90% while using a single-image-per-eye, as well as rarely requiring dilation. Each of these innovations is key to making screening more accessible and practical. The solution is currently being deployed in primary care clinics to help address the care gaps that result from less than 50% of patients currently undergoing the yearly recommended retinal screenings.

“This has the potential to revolutionize preventive screening, allowing for screening guidelines which reflect individual risk and enabling personalized risk management,” says Zack Dvey-Aharon, Ph.D., CEO of AEYE Health.

13 tykkäystä

Uusi tutkimusartikkeli julkaistu Intiasta. Käytössä oli Optomedin valmistama Zeiss Visuscout (Optomedin omia kameroitahan ei ole Intiassa myynnissä). Tuloksista päätellen OEM-myynti vetää kovalla imulla Intiassa ja muuallakin jatkossakin.

Using deep learning to detect diabetic retinopathy on handheld non-mydriatic retinal images acquired by field workers in community settings

As part of the SMART India study, a cross-sectional study conducted across 20 regions in India, in this work-package we developed and evaluated a deep learning-based system (DLS) in detecting referable DR.

In conclusion, our study highlights the efficacy of automated deep learning-based detection of referable DR and DME using handheld non-mydriatic retinal images in community settings. Our findings have particular relevance for policy makers in LMIC aiming to implement cost-effective, scalable and sustainable DR screening programmes.

https://www.nature.com/articles/s41598-023-28347-z

13 tykkäystä

Optomedin vanha tuttu Paolo S. Silva puhui Retina 2023 tilaisuudessa:

Telemedicine, imaging innovations and artificial intelligence could help address the burden of screening in diabetic retinal care, according to a speaker at Retina 2023.

Paolo S. Silva, MD, said despite well-established guidelines for diabetic retinopathy screening, barriers to care — including out-of-pocket costs, availability of eye care providers, and patient and provider awareness — remain.

“The future of retinal imaging needs to move away from tertiary medical care settings and go to where the patients are,” Silva said. “Diabetic retinopathy screening programs have the potential to be deployed in a wide geographic area and access a diverse patient population. This can be achieved using less expensive and improved ultra-portable imaging devices, as well as increasing patient participation in their imaging.”

With these advances come more images, which call for more evaluation. Artificial intelligence could help evaluate patients and reduce the caseload burden of reading centers, Silva said.

2 tykkäystä